{"ok":true,"entry":{"slug":"tirzepatide","kind":"medication","name":"tirzepatide","aliases":["Mounjaro","Zepbound"],"brands_sg":["Mounjaro"],"class":"GIP/GLP-1 receptor agonist","tags":["diabetes"],"use_for":"type 2 diabetes in adults, alongside diet and exercise","use_after":"once a week, any time of day, with or without meals","use_duration":null,"take_with":"injected under the skin of the abdomen, thigh or upper arm","pros":["sg label: one injection a week, any time of day","sg label: no dose change for renal or liver impairment","sg label: a missed dose has a 4-day catch-up window"],"cons":["the sg licence covers type 2 diabetes, not weight loss","nhs: nausea, vomiting and bowel changes are common","nhs: acute pancreatitis and gallstones are rare risks"],"dose_note":"the sg mounjaro label (sin16714p) states \"The starting dose of tirzepatide is 2.5 mg once weekly … The recommended maintenance doses are 5 mg, 10 mg and 15 mg. The maximum dose is 15 mg once weekly\", with increases \"in 2.5 mg increments after a minimum of 4 weeks on the current dose\" — as directed on the label or by your doctor","dosage":null,"ul_status":null,"sg_class":"prescription-only","cautions":["pregnancy and breastfeeding — nhs: not used in either, and it advises stopping at least 4 weeks before trying to conceive","a past or present inflamed pancreas (acute pancreatitis) — nhs lists it among reasons it may not be suitable","already on insulin or a sulphonylurea — sg label: a dose reduction of those may be considered to reduce hypoglycaemia risk","using hormonal contraception — nhs: additional barrier contraception for 4 weeks after starting and after each dose increase"],"clashes":[{"src":["nhs_tirzepatide_int"],"note":"nhs lists them among medicines that may not mix well with tirzepatide","with":"other diabetes medicines (gliclazide, glimepiride, metformin, tolbutamide)"},{"src":["nhs_tirzepatide_int","ndf_mounjaro_hypo"],"note":"nhs: a doctor or specialist nurse may need to adjust the insulin dose; the sg label also flags hypoglycaemia risk","with":"insulin"},{"src":["nhs_tirzepatide_int"],"note":"nhs lists some medicines to prevent blood clots among those that may not mix well","with":"warfarin and other clot-prevention medicines"},{"src":["nhs_tirzepatide_int"],"note":"nhs: the healthcare professional should be told that tirzepatide is being used","with":"a general anaesthetic or sedative for surgery or dental work"},{"src":["nhs_tirzepatide_int"],"food":true,"note":"nhs: best avoided because it can increase side effects such as nausea or vomiting","with":"alcohol"}],"sources":[{"id":"hsa_register","url":"https://data.gov.sg/api/action/datastore_search?resource_id=d_767279312753558cbf19d48344577084&limit=6000","label":"HSA — Listing of Registered Therapeutic Products (data.gov.sg dataset d_767279312753558cbf19d48344577084), Forensicclassification column; all 5,511 rows cached at /tmp/hsa_all.json and filtered locally, 27 Aug 2026","quote":"MOUNJARO INJECTION 5MG/0.5ML SIN16714P | Tirzepatide | Prescription Only | A10BX16; MOUNJARO KwikPen SIN17257P–SIN17262P; MOUNJARO SOLUTION FOR INJECTION IN VIAL SIN17351P–SIN17356P — all 18 tirzepatide rows 'Prescription Only'; no ZEPBOUND row exists","accessed":"2026-08-27"},{"id":"ndf_mounjaro","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16714p/","label":"MOH National Drug Formulary (Singapore) — MOUNJARO INJECTION 5MG/0.5ML [SIN16714P], product information and forensic classification","quote":"TIRZEPATIDE - 5 MG/0.5 ML … Registration Number SIN16714P … Licence Holder DKSH SINGAPORE PTE. LTD. … Forensic Classification PRESCRIPTION ONLY MEDICINES … ATC code A10BX16 … Prescription-only Medicines with Exemptions for Supply without Prescription: NA","accessed":"2026-08-27"},{"id":"ndf_mounjaro_ind","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16714p/","label":"MOH National Drug Formulary (Singapore) — MOUNJARO [SIN16714P], 4.1 Therapeutic indications","quote":"Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise … in addition to other medicinal products for the treatment of diabetes","accessed":"2026-08-27"},{"id":"ndf_mounjaro_dose","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16714p/","label":"MOH National Drug Formulary (Singapore) — MOUNJARO [SIN16714P], 4.2 Posology: maintenance and maximum dose","quote":"The starting dose of tirzepatide is 2.5 mg once weekly … The recommended maintenance doses are 5 mg, 10 mg and 15 mg. The maximum dose is 15 mg once weekly","accessed":"2026-08-27"},{"id":"ndf_mounjaro_hypo","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16714p/","label":"MOH National Drug Formulary (Singapore) — MOUNJARO [SIN16714P], 4.2 Posology: combination with a sulphonylurea or insulin","quote":"When tirzepatide is added to existing therapy of a sulphonylurea and/or insulin, a reduction in the dose of sulphonylurea or insulin may be considered to reduce the risk of hypoglycaemia","accessed":"2026-08-27"},{"id":"ndf_mounjaro_admin","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16714p/","label":"MOH National Drug Formulary (Singapore) — MOUNJARO [SIN16714P], 4.2 Method of administration and missed doses","quote":"Mounjaro is to be injected subcutaneously in the abdomen, thigh or upper arm. The dose can be administered at any time of day, with or without meals. Injection sites should be rotated with each dose","accessed":"2026-08-27"},{"id":"ndf_mounjaro_special","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16714p/","label":"MOH National Drug Formulary (Singapore) — MOUNJARO [SIN16714P], 4.2 Special populations and missed doses","quote":"No dose adjustment is required for patients with renal impairment including end stage renal disease (ESRD) … No dose adjustment is required for patients with hepatic impairment","accessed":"2026-08-27"},{"id":"ndf_mounjaro_missed","url":"https://www.ndf.gov.sg/about-drugs/product-information/sin16714p/","label":"MOH National Drug Formulary (Singapore) — MOUNJARO [SIN16714P], 4.2 Posology: missed doses","quote":"If a dose is missed, it should be administered as soon as possible within 4 days after the missed dose. If more than 4 days have passed, skip the missed dose","accessed":"2026-08-27"},{"id":"nhs_tirzepatide","url":"https://www.nhs.uk/medicines/tirzepatide/","label":"NHS medicines A–Z — Tirzepatide (common brands: Mounjaro), page last reviewed 15 May 2026","quote":"Tirzepatide is a type of medicine called a GLP-1/GIP agonist … It's only available with a prescription … Tirzepatide comes as an injection that you use once a week … you can have it any time of day","accessed":"2026-08-27"},{"id":"nhs_tirzepatide_se","url":"https://www.nhs.uk/medicines/tirzepatide/","label":"NHS medicines A–Z — Tirzepatide, side effects and who cannot use it","quote":"Common side effects of tirzepatide include: feeling sick (nausea) or being sick (vomiting), constipation or diarrhoea, stomach pain … an inflamed pancreas (acute pancreatitis) … gallstones or swelling of the gallbladder","accessed":"2026-08-27"},{"id":"nhs_tirzepatide_int","url":"https://www.nhs.uk/medicines/tirzepatide/","label":"NHS medicines A–Z — Tirzepatide, using it with other medicines, food and drink","quote":"other diabetes medicines, such as gliclazide, glimepiride, metformin and tolbutamide; some medicines to prevent blood clots, such as warfarin; insulin … a general anaesthetic … or a sedative … It's best to avoid drinking alcohol","accessed":"2026-08-27"},{"id":"nhs_tirzepatide_preg","url":"https://www.nhs.uk/medicines/tirzepatide/","label":"NHS medicines A–Z — Tirzepatide, pregnancy, breastfeeding and contraception","quote":"Tirzepatide is not used during pregnancy … If you want to become pregnant, you should stop using tirzepatide at least 4 weeks before you start trying … It's important to use an additional barrier contraception … for 4 weeks after starting","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:33.302383+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}